drugset / Trial / NCT04591626
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
Timeline
- Start
- 2020-12-07
- Primary completion
- 2022-04-28
- Completion
- 2022-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |
| Background | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |